Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma
Abstract Background Anti-PD1-Checkpoint inhibition (CI) is an established treatment of recurrent and/or metastatic head and neck cancer. A potential benefit from CI in early-stage disease that is usually treated by radiation or surgery has not been investigated so far and is currently not addressed...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-05-01
|
| Series: | Journal of Otolaryngology - Head and Neck Surgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40463-022-00572-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849406618707427328 |
|---|---|
| author | Maximilian Linxweiler Jan Philipp Kühn Christian Neubert Fadi Khreish Benedikt Balensiefer Mathias Wagner Bernhard Schick |
| author_facet | Maximilian Linxweiler Jan Philipp Kühn Christian Neubert Fadi Khreish Benedikt Balensiefer Mathias Wagner Bernhard Schick |
| author_sort | Maximilian Linxweiler |
| collection | DOAJ |
| description | Abstract Background Anti-PD1-Checkpoint inhibition (CI) is an established treatment of recurrent and/or metastatic head and neck cancer. A potential benefit from CI in early-stage disease that is usually treated by radiation or surgery has not been investigated so far and is currently not addressed in clinical trials. Case presentation A 58-year-old man was diagnosed with a cT2 supraglottic laryngeal cancer and a synchronous metastasized adenocarcinoma of the lung. As the patient refused any treatment of his laryngeal cancer, he received combined immune-chemotherapy according to the KEYNOTE-189 protocol. After 4 cycles of pembrolizumab/carboplatin/pemetrexed, the patient showed a complete remission of his laryngeal cancer with a clear shrinkage of the mediastinal and hilar lung cancer metastases. After 21 cycles of maintenance therapy, the lung adenocarcinoma shows a stable disease status with no signs of any residual or recurrent laryngeal cancer. Conclusions Anti-PD1-CI may be a treatment option also for early-stage HNSCC with excellent functional outcome when established therapies are not available. Graphical Abstract |
| format | Article |
| id | doaj-art-4ca0b8a1db0a4878b116faaf1e5ac680 |
| institution | Kabale University |
| issn | 1916-0216 |
| language | English |
| publishDate | 2022-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Otolaryngology - Head and Neck Surgery |
| spelling | doaj-art-4ca0b8a1db0a4878b116faaf1e5ac6802025-08-20T03:36:19ZengSAGE PublishingJournal of Otolaryngology - Head and Neck Surgery1916-02162022-05-015111710.1186/s40463-022-00572-yComplete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinomaMaximilian Linxweiler0Jan Philipp Kühn1Christian Neubert2Fadi Khreish3Benedikt Balensiefer4Mathias Wagner5Bernhard Schick6Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical CenterDepartment of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical CenterDepartment of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical CenterDepartment of Nuclear Medicine, Saarland University Medical CenterDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, Saarland University Medical CenterDepartment of General and Surgical Pathology, Saarland University Medical CenterDepartment of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical CenterAbstract Background Anti-PD1-Checkpoint inhibition (CI) is an established treatment of recurrent and/or metastatic head and neck cancer. A potential benefit from CI in early-stage disease that is usually treated by radiation or surgery has not been investigated so far and is currently not addressed in clinical trials. Case presentation A 58-year-old man was diagnosed with a cT2 supraglottic laryngeal cancer and a synchronous metastasized adenocarcinoma of the lung. As the patient refused any treatment of his laryngeal cancer, he received combined immune-chemotherapy according to the KEYNOTE-189 protocol. After 4 cycles of pembrolizumab/carboplatin/pemetrexed, the patient showed a complete remission of his laryngeal cancer with a clear shrinkage of the mediastinal and hilar lung cancer metastases. After 21 cycles of maintenance therapy, the lung adenocarcinoma shows a stable disease status with no signs of any residual or recurrent laryngeal cancer. Conclusions Anti-PD1-CI may be a treatment option also for early-stage HNSCC with excellent functional outcome when established therapies are not available. Graphical Abstracthttps://doi.org/10.1186/s40463-022-00572-yHead and neck cancerImmunotherapyEarly-stage diseasePembrolizumab |
| spellingShingle | Maximilian Linxweiler Jan Philipp Kühn Christian Neubert Fadi Khreish Benedikt Balensiefer Mathias Wagner Bernhard Schick Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma Journal of Otolaryngology - Head and Neck Surgery Head and neck cancer Immunotherapy Early-stage disease Pembrolizumab |
| title | Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma |
| title_full | Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma |
| title_fullStr | Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma |
| title_full_unstemmed | Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma |
| title_short | Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma |
| title_sort | complete remission of an early stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma |
| topic | Head and neck cancer Immunotherapy Early-stage disease Pembrolizumab |
| url | https://doi.org/10.1186/s40463-022-00572-y |
| work_keys_str_mv | AT maximilianlinxweiler completeremissionofanearlystagelaryngealcancerundercombinedpembrolizumabandchemotherapytreatmentofasynchronouslungadenocarcinoma AT janphilippkuhn completeremissionofanearlystagelaryngealcancerundercombinedpembrolizumabandchemotherapytreatmentofasynchronouslungadenocarcinoma AT christianneubert completeremissionofanearlystagelaryngealcancerundercombinedpembrolizumabandchemotherapytreatmentofasynchronouslungadenocarcinoma AT fadikhreish completeremissionofanearlystagelaryngealcancerundercombinedpembrolizumabandchemotherapytreatmentofasynchronouslungadenocarcinoma AT benediktbalensiefer completeremissionofanearlystagelaryngealcancerundercombinedpembrolizumabandchemotherapytreatmentofasynchronouslungadenocarcinoma AT mathiaswagner completeremissionofanearlystagelaryngealcancerundercombinedpembrolizumabandchemotherapytreatmentofasynchronouslungadenocarcinoma AT bernhardschick completeremissionofanearlystagelaryngealcancerundercombinedpembrolizumabandchemotherapytreatmentofasynchronouslungadenocarcinoma |